The application of FGFR inhibitors in prostate cancer
The abnormal expression or activation of fibroblast growth factor receptors(fibroblast growth factor receptor,FGFR)is closely related to the occurrence and development of tumors,and small molecule inhibitors targeting FGFRs have become a research hotspot in recent years.Erdafitinib,as the first FGFR small molecule inhibitor,has been approved by the US FDA for use in advanced prostate cancer with FGFR gene mutations.Multiple FGFR inhibitors in clinical trials have also shown satisfactory therapeutic effects.This article provided a review of FGFR structure,FGFR signaling pathway,FGFR inhibitors,and their drug resistance patterns,with the aim of providing reference for the clinical application of FGFR inhibitors in prostate cancer.
国家科技期刊平台
NSTL
万方数据
